The Ensemble Team

Kyle Okimoto, the firm's CEO, leads investment decisions with significant input from his brother and CTO James Okimoto. The firm operates with a flat structure; there is no formal investment committee beyond the two co-founders. This tight decision-making loop is designed to move at the speed of technical diligence rather than through layers of institutional approval.

Ensemble relies heavily on inbound technical founder networks and research communities around applied machine learning. Because the firm's own engineers actively contribute to open-source projects and publish technical work, many founders self-identify and approach directly. The Cedars-Sinai partnership, announced in 2021, represents a thematic sourcing channel for digital health opportunities sourced from clinical practice gaps rather than pitch decks.

It functions as a pure venture studio, not a traditional fund. The firm deploys its own capital alongside select co-investors and provides embedded engineering resources to portfolio companies. There is no external LP base — the Okimoto brothers initially self-funded operations and sustain through equity returns rather than management fees.

The firm only makes direct investments into operating companies. There is no evidence of fund-of-funds activity or investments into external VC partnerships. The studio model specifically avoids passive limited-partner positions in favor of active engineering engagement.

Ensemble invests on an opportunistic, deal-by-deal basis without a formal fund vehicle or periodic capital raises. Forbes reported in 2021 that the firm had deployed $10 million since inception without closing a traditional venture fund. This structure eliminates fund-cycle pressure and allows the firm to co-invest alongside strategic partners project by project.